| 122.58 Data as of May 24 |  -1.06 / -0.86%Today’s Change | 58.53 Today|||52-Week Range 131.82 | +56.21% Year-to-Date |
| Encouraging News for Peregrine Pharma - Analyst Blog May 24 / Zacks.com | Gilead's Sofosbuvir under European Review - Analyst Blog May 22 / Zacks.com |
| Priority FDA Review for Celgene's Abraxane - Analyst Blog May 24 / Zacks.com | This Is Incredibly Bullish Behavior May 22 / TheStreet.com |
| NPS Pharma Prices Offering - Analyst Blog May 23 / Zacks.com | Cramer: A Pile of Simply Horrendous Advice May 20 / TheStreet.com |
| Encouraging News for Peregrine Pharma - Analyst Blog May 23 / Zacks.com | Myriad Soars Higher on Celeb Clout - Analyst Blog May 15 / Zacks.com |
| 5 Stocks Raising The Drugs Industry Higher May 23 / TheStreet.com | Wider-Than-Expected Loss at Athersys - Analyst Blog May 15 / Zacks.com |
| Previous close | 123.64 |
| Today’s open | 122.61 |
| Day’s range | 121.66 - 123.71 |
| Volume | 2,286,520 |
| Average volume (3 months) | 3,199,165 |
| Market cap | $51.1B |
| Dividend yield | -- |
| Earnings growth (last year) | +15.79% |
| Earnings growth (this year) | +16.56% |
| Earnings growth (next 5 years) | +23.00% |
| Revenue growth (last year) | +12.05% |
| P/E ratio | 37.3 |
| Price/Sales | 6.23 |
| Price/Book | 9.04 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +0.28 | +0.75% |
| LLYEli Lilly and Co | -0.60 | -1.10% |
| AZNAstraZeneca PLC | +0.09 | +0.17% |
| ABBVAbbVie Inc | -1.15 | -2.47% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | $1.43 |
| Annual revenue (last year) | $5.4B |
| Annual profit (last year) | $1.5B |
| Net profit margin | 26.84% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Robert J. Hugin, MBA |
Chief Operating Officer & Executive Vice President Perry A. Karsen |
Corporate headquarters Summit, New Jersey |
.
